Amarin Co. plc (NASDAQ:AMRN) General Counsel Joseph T. Kennedy sold 44,857 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $3.73, for a total value of $167,316.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Amarin Co. plc (NASDAQ AMRN) remained flat at $$3.48 during trading on Friday. 1,804,739 shares of the stock traded hands, compared to its average volume of 2,580,000. The stock has a market cap of $942.66, a PE ratio of -12.89 and a beta of 0.50. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32. Amarin Co. plc has a 52-week low of $2.85 and a 52-week high of $4.60.
A number of brokerages have issued reports on AMRN. BidaskClub lowered Amarin from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. ValuEngine upgraded Amarin from a “sell” rating to a “hold” rating in a research note on Saturday, November 4th. Zacks Investment Research lowered Amarin from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Cantor Fitzgerald set a $10.00 price target on Amarin and gave the stock a “buy” rating in a research note on Tuesday, January 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Amarin in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Amarin presently has an average rating of “Hold” and a consensus target price of $7.75.
Amarin Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.